Chemical Biology and Early Stages of Drug Discovery

化学生物学和药物发现的早期阶段

基本信息

  • 批准号:
    RGPIN-2015-05529
  • 负责人:
  • 金额:
    $ 3.28万
  • 依托单位:
  • 依托单位国家:
    加拿大
  • 项目类别:
    Discovery Grants Program - Individual
  • 财政年份:
    2016
  • 资助国家:
    加拿大
  • 起止时间:
    2016-01-01 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

A key objective of our research program is the design and synthesis of molecular tools that can be used to probe the therapeutic value of biological targets. A related objective is the optimization of hit and lead compounds into pre-clinical candidates. These efforts mandate the development of efficient synthetic protocols that are amenable to modular, high throughput preparation of structurally diverse compound libraries. Fundamental to our research is the implementation of structural tools to guide our medicinal chemistry efforts. This proposal describes three of our projects, focusing on the human enzymes: 1. farnesyl pyrophosphate synthase (hFPPS), 2. geranylgeranyl pyrophosphate synthase (hGGPPS), and 3. the zinc metalloproteinase ZMPSTE24. Human FPPS and GGPPS control the levels of human isoprenoids and the post-translational prenylation of all small GTPase proteins that are crucially important in cell signalling, cell proliferation and neuronal synaptic plasticity. Recently, we reported the discovery of novel pyridine-, thienopyrimidine- and indole-based inhibitors of hFPPS that bind to the active site and/or a catalytically relevant allosteric pocket of the enzyme. The design and synthesis of optimized hFPPS allosteric inhibitors will be one of the key topics in this proposal. Structural remodelling of these compounds will include conformational rigidification to mimic the enzyme-bound conformation, the asymmetric synthesis of a-aminophosphonic acids and the synthesis of cyclic phostones that are key pharmacophores for this target. In contrast to hFPPS (which is already a clinically validated biological target), little is known about the consequences of inhibiting selectively hGGPPS or ZMPSTE24 in vivo. Only few weak inhibitors of these enzymes are known and limited structural information on ligand/protein interactions have been reported. Our research projects aim to provide valuable insight into the role of these proteins in neurodegeneration (hGGPPS) and oncogenesis (ZMPSTE24). Statistic Canada has recently reported that 30% of all deaths amongst Canadians are due to cancer. Additionally, in 2010, the WHO estimated the prevalence of dementia to be 35.6 million worldwide and expected to increase to 65.7 million by 2030. Therefore, there is enormous need for the validation of new targets for the treatment of cancer and neurodegeneration. The main priority of our research is to provide molecular tools that can guide drug discovery efforts in these two important disease areas. Our studies are truly multidisciplinary and involve a seamless integration of synthetic organic chemistry, structural research and biochemistry. I believe that our program provides an excellent training ground for students and research fellows (HQPs) interested in pursuing an academic or industrial career in biomedical or pharmaceutical sciences.
我们研究计划的一个关键目标是设计和合成可用于探测生物靶点治疗价值的分子工具。一个相关的目标是将命中和先导化合物优化为临床前候选物。这些努力要求开发有效的合成方案,其适合于结构多样的化合物文库的模块化、高通量制备。我们研究的基础是实施结构工具来指导我们的药物化学工作。该提案描述了我们的三个项目,重点是人类酶:1。法呢基焦磷酸合酶(hFPPS),2.香叶基香叶基焦磷酸合酶(hGGPPS),和3.锌金属蛋白酶ZMPSTE 24。 人FPPS和GGPPS控制人类异戊二烯的水平和所有小GT3蛋白的翻译后异戊烯化,其在细胞信号传导、细胞增殖和神经元突触可塑性中至关重要。最近,我们报道了新的吡啶,噻吩并嘧啶和吲哚为基础的抑制剂的hFPPS结合的活性位点和/或催化相关的变构口袋的酶的发现。优化hFPPS变构抑制剂的设计和合成将是本研究的重点课题之一。这些化合物的结构重塑将包括构象刚性化以模拟酶结合构象、α-氨基膦酸的不对称合成和作为该靶标的关键药效团的环状phostone的合成。与hFPPS(其已经是临床验证的生物靶标)相反,关于选择性抑制hGGPPS或ZMPSTE 24在体内的后果知之甚少。只有少数弱抑制剂,这些酶是已知的和有限的配体/蛋白质相互作用的结构信息已被报道。我们的研究项目旨在为这些蛋白质在神经变性(hGGPPS)和肿瘤发生(ZMPSTE 24)中的作用提供有价值的见解。 加拿大统计局最近报告说,30%的加拿大人死于癌症。此外,2010年,世界卫生组织估计全世界痴呆症的患病率为3560万,预计到2030年将增加到6570万。因此,对于用于治疗癌症和神经变性的新靶点的验证存在巨大的需求。我们研究的主要优先事项是提供分子工具,可以指导这两个重要疾病领域的药物发现工作。 我们的研究是真正的多学科研究,涉及合成有机化学、结构研究和生物化学的无缝集成。我相信,我们的计划为有兴趣在生物医学或制药科学领域从事学术或工业职业的学生和研究员(HQP)提供了一个很好的培训基地。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tsantrizos, Youla其他文献

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
  • DOI:
    10.1021/ml500002n
  • 发表时间:
    2014-04-01
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Fader, Lee D.;Malenfant, Eric;Tsantrizos, Youla
  • 通讯作者:
    Tsantrizos, Youla

Tsantrizos, Youla的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tsantrizos, Youla', 18)}}的其他基金

Engineering Phosphorus-Containing Molecules as Leads for Medicinal Chemistry and as Tools for Asymmetric Synthesis
工程化含磷分子作为药物化学的先导化合物和不对称合成的工具
  • 批准号:
    RGPIN-2020-04049
  • 财政年份:
    2022
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Engineering Phosphorus-Containing Molecules as Leads for Medicinal Chemistry and as Tools for Asymmetric Synthesis
工程化含磷分子作为药物化学的先导化合物和不对称合成的工具
  • 批准号:
    RGPIN-2020-04049
  • 财政年份:
    2021
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Engineering Phosphorus-Containing Molecules as Leads for Medicinal Chemistry and as Tools for Asymmetric Synthesis
工程化含磷分子作为药物化学的先导化合物和不对称合成的工具
  • 批准号:
    RGPIN-2020-04049
  • 财政年份:
    2020
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
NMR Systems Upgrade for a Sustainable New Era
核磁共振系统升级,迎接可持续发展的新时代
  • 批准号:
    RTI-2020-00491
  • 财政年份:
    2019
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Research Tools and Instruments
Chemical Biology and Early Stages of Drug Discovery
化学生物学和药物发现的早期阶段
  • 批准号:
    RGPIN-2015-05529
  • 财政年份:
    2019
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Chemical Biology and Early Stages of Drug Discovery
化学生物学和药物发现的早期阶段
  • 批准号:
    RGPIN-2015-05529
  • 财政年份:
    2018
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Chemical Biology and Early Stages of Drug Discovery
化学生物学和药物发现的早期阶段
  • 批准号:
    RGPIN-2015-05529
  • 财政年份:
    2017
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Chemical Biology and Early Stages of Drug Discovery
化学生物学和药物发现的早期阶段
  • 批准号:
    RGPIN-2015-05529
  • 财政年份:
    2015
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Design and synthesis of molecular tools that modulate metabolic pathways- implications for drug discovery
调节代谢途径的分子工具的设计和合成——对药物发现的影响
  • 批准号:
    121762-2010
  • 财政年份:
    2014
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual
Design and synthesis of molecular tools that modulate metabolic pathways- implications for drug discovery
调节代谢途径的分子工具的设计和合成——对药物发现的影响
  • 批准号:
    121762-2010
  • 财政年份:
    2013
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Discovery Grants Program - Individual

相似国自然基金

Journal of Integrative Plant Biology
  • 批准号:
    31024801
  • 批准年份:
    2010
  • 资助金额:
    24.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

NSF Postdoctoral Fellowship in Biology: Pollinator Thermal Performance and Limitation in an Early-Blooming Crop
美国国家科学基金会生物学博士后奖学金:早花作物的传粉媒介热性能和限制
  • 批准号:
    2305941
  • 财政年份:
    2023
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Fellowship Award
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD
辅助来源研究:早期 COPD 中小气道基底细胞生物学的特征
  • 批准号:
    10736644
  • 财政年份:
    2023
  • 资助金额:
    $ 3.28万
  • 项目类别:
NSF Postdoctoral Fellowship in Biology: Rewriting the Code: Elucidating how early life adversity alters DNA to affect amygdala-related behavior
NSF 生物学博士后奖学金:重写代码:阐明早年逆境如何改变 DNA 从而影响杏仁核相关行为
  • 批准号:
    2208822
  • 财政年份:
    2023
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Fellowship Award
A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor Biology
用于膀胱癌早期检测的多重蛋白质生物标志物免疫测定及其在肿瘤生物学中的意义
  • 批准号:
    10591629
  • 财政年份:
    2023
  • 资助金额:
    $ 3.28万
  • 项目类别:
Core-based scientist specializing in high throughput screening for early drug discovery, target identification and systems biology analysis of cancer
专注于癌症早期药物发现、靶标识别和系统生物学分析的高通量筛选的核心科学家
  • 批准号:
    10469395
  • 财政年份:
    2022
  • 资助金额:
    $ 3.28万
  • 项目类别:
Core-based scientist specializing in high throughput screening for early drug discovery, target identification and systems biology analysis of cancer
专注于癌症早期药物发现、靶标识别和系统生物学分析的高通量筛选的核心科学家
  • 批准号:
    10545491
  • 财政年份:
    2022
  • 资助金额:
    $ 3.28万
  • 项目类别:
Systems Biology of Early Atopy (SUNBEAM) Analysis and Bioinformatics Center
早期特应性系统生物学(SUNBEAM)分析和生物信息学中心
  • 批准号:
    10573523
  • 财政年份:
    2022
  • 资助金额:
    $ 3.28万
  • 项目类别:
CAREER: Reproductive mode and horizontal gene transfer in nematode worms: Training early career researchers in computational evolutionary biology
职业:线虫的繁殖模式和水平基因转移:培训计算进化生物学的早期职业研究人员
  • 批准号:
    2225796
  • 财政年份:
    2022
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Continuing Grant
Early Research Experiences and Mentoring to Increase the Numbers of Biology and Chemistry Graduates Prepared for Careers in Science
早期研究经验和指导,以增加为科学职业做好准备的生物学和化学毕业生的数量
  • 批准号:
    2030621
  • 财政年份:
    2021
  • 资助金额:
    $ 3.28万
  • 项目类别:
    Standard Grant
Early Life Adversity and the Developmental Programming of Early Childhood Telomere Biology: A Longitudinal Study of Developmental Context and Behavioral Mediators
早期生活逆境与幼儿期端粒生物学的发展规划:发展背景和行为中介的纵向研究
  • 批准号:
    10297293
  • 财政年份:
    2021
  • 资助金额:
    $ 3.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了